Sean A. Mc Carthy Cytom X Therapeutics, Inc. (CTMX) insider trading activity

CTMX Quotes by TradingView

Sean A. Mc Carthy is CEO of CytomX Therapeutics, Inc.. Currently has a direct ownership of 634,249 shares of CTMX, which is worth approximately $856,236. The most recent transaction as insider was on Mar 26, 2024, when has been sold 109,768 shares (Common Stock) at a price of $1.57 per share, resulting in proceeds of $172,335. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 634K
0% 3M change
56.47% 12M change
Total Value Held $856,236

Sean A. McCarthy Transaction History

Date Transaction Value Shares Traded Shares Held Form
Mar 26 2024
BUY
Exercise of conversion of derivative security
$172,335 $1.57 p/Share
109,768 Added 14.75%
634,249 Common Stock
Mar 19 2024
SELL
Open market or private sale
$42,266 $2.09 p/Share
20,223 Reduced 3.71%
524,481 Common Stock
Jan 18 2024
BUY
Grant, award, or other acquisition
-
90,000 Added 14.18%
544,704 Common Stock
Dec 20 2023
SELL
Open market or private sale
$18,700 $1.38 p/Share
13,551 Reduced 2.89%
454,704 Common Stock
Dec 17 2023
BUY
Exercise of conversion of derivative security
-
37,500 Added 7.41%
468,255 Common Stock
Sep 22 2023
SELL
Open market or private sale
$18,981 $1.3 p/Share
14,601 Reduced 3.28%
430,755 Common Stock
Sep 20 2023
BUY
Grant, award, or other acquisition
-
40,000 Added 8.24%
445,356 Common Stock
May 19 2023
BUY
Exercise of conversion of derivative security
$25,959 $1.57 p/Share
16,535 Added 3.92%
405,356 Common Stock
Mar 16 2023
SELL
Open market or private sale
$13,387 $1.88 p/Share
7,121 Reduced 1.8%
388,821 Common Stock
Feb 02 2023
BUY
Grant, award, or other acquisition
-
105,000 Added 20.96%
395,942 Common Stock
Jul 20 2022
SELL
Open market or private sale
$21,174 $1.42 p/Share
14,911 Reduced 4.88%
290,942 Common Stock
Jul 19 2022
BUY
Grant, award, or other acquisition
-
40,000 Added 11.57%
305,853 Common Stock
May 09 2022
BUY
Exercise of conversion of derivative security
$85,475 $0.94 p/Share
90,931 Added 25.49%
265,853 Common Stock
Feb 02 2022
BUY
Grant, award, or other acquisition
-
75,000 Added 30.01%
174,922 Common Stock
Aug 11 2021
BUY
Exercise of conversion of derivative security
$104,088 $1.13 p/Share
92,113 Added 47.97%
99,922 Common Stock
Jun 14 2021
BUY
Exercise of conversion of derivative security
$42 $1.04 p/Share
40 Added 0.51%
7,849 Common Stock
Mar 31 2021
SELL
Open market or private sale
$749,000 $7.49 p/Share
100,000 Reduced 32.58%
206,894 Common Stock
Mar 31 2021
BUY
Exercise of conversion of derivative security
$113,000 $1.13 p/Share
100,000 Added 24.58%
306,894 Common Stock
Dec 23 2020
BUY
Exercise of conversion of derivative security
$113,000 $1.13 p/Share
100,000 Added 32.58%
206,894 Common Stock
Nov 30 2020
BUY
Grant, award, or other acquisition
$5,943 $6.39 p/Share
930 Added 0.86%
106,894 Common Stock
Sep 30 2019
SELL
Bona fide gift
-
4,500 Reduced 36.56%
7,809 Common Stock
SAM

Sean A. Mc Carthy

CEO
South San Francisco, CA

Track Institutional and Insider Activities on CTMX

Follow CytomX Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CTMX shares.

Notify only if

Insider Trading

Get notified when an Cytom X Therapeutics, Inc. insider buys or sells CTMX shares.

Notify only if

News

Receive news related to CytomX Therapeutics, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on CTMX